Voxilaprevir

Therapeutic

Vosevi (Voxilaprevir/Sofosbuvir/Velpatasvir) is approved for use in patients with chronic Hepatitis C genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor

Structural features

SMILES

CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C

Sequence

-

Molar mass

868.94 g/mol

Constitutional members:

5

Natural amino acids

0

D-Amino acids

0

N-terminus

cycle

C-terminus

cyclopropanesulfonamide

Cyclic

yes

Members/cycle

3

Bond to form cycle

side chain-to-tail

Lipidation

no

Glycosylation

no

Route of administration

ORAL

Terminal half-life

33 hours

Protein binding

Voxilaprevir is more than 99% bound to human plasma proteins

Absorption and Bioavailability

-

References